CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIC

精神分裂症患者长期服用安非他明

• 批准号: 3860021
• 负责人: L B BIGELOW
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3860021
• 关键词: amphetamines; clinical trials; disabling disease; dosage; human subject; human therapy evaluation; mental disorder chemotherapy; schizophrenia; sign /symptom

Persistent deficit symptoms represent the most disabling of the schizophrenic symptoms that are likely to remain after the productive or positive symptoms are treated with available neuroleptics. Those patients who appear to benefit from the acute administration of amphetamine are asked to participate in a 6 week trial of daily oral dosing with amphetamine. To date, two patients have completed this double blind placebo controlled trial. One appeared to benefit modestly, the other showed no obvious change. Formal statistical analysis will await the acculmination of adequate numbers of patients.

持续的缺乏症状代表了最严重的障碍 精神分裂症症状在生产或生产后可能仍然存在 阳性症状可用可用的抗精神病药物治疗。 那些病人 那些似乎从急性服用安非他明中受益的人是 被要求参加一项为期 6 周的每日口服给药试验 安非他明。 迄今为止，已有两名患者完成了这项双盲安慰剂对照研究 审判。 一个似乎受益匪浅，另一个则没有明显受益 改变。 正式的统计分析有待积累 足够数量的患者。